Endocrine Abstracts

Purpose of Study: Sodium-glucose cotransporter-2 inhibitors (SGLT-2i) and testosterone replacement therapy (TRT) can increase red blood cell production through different mechanisms. Little is known if combination therapy poses risk of erythrocytosis (ERY) in real world clinical practice.Methods: This was a retrospective nationwide cohort study of US Veterans with type 2 diabetes (T2D) without prior history of ERY who were prescribed SGLT-2i and/or TRT be...